MingMed is a technology company.
MingMed has raised $110.0M across 2 funding rounds.
MingMed has raised $110.0M in total across 2 funding rounds.
MingMed has raised $110.0M in total across 2 funding rounds.
MingMed's investors include Gaorong Capital, Lightspeed China Partners.
MingMed Biotechnology Co., Ltd. is a clinical-stage biopharmaceutical company based in Guangzhou, China, focused on the in-house discovery and development of novel drugs addressing global unmet medical needs.[1][2][3] It builds a portfolio of first-in-class candidates across four synergistic therapeutic areas: ophthalmic drugs, recombinant botulinum toxin, immuno-oncology drugs, and pet immune drugs, with major products in clinical stages and nearing commercialization.[1][2][5] MingMed serves pharmaceutical sectors needing innovative solutions for conditions like age-related macular degeneration, macular dystrophy, glabellar frown lines, and solid tumors, solving unmet needs through efficient R&D led by top global scientists.[1][3][5] Founded in 2019, it has raised $110M in funding, including a $50M Series A-II round four years ago, signaling strong growth momentum in China's booming biotech ecosystem.[3]
MingMed was founded in October 2019 in Guangzhou's Nansha District by a team including Mingguo Huang, Yan Zhang, and Xuebin Liao, leveraging their expertise to pioneer original drug development.[3][4] The idea emerged amid China's push for innovative pharmaceuticals, with the company establishing headquarters in Guangdong Medical Valley to capitalize on the region's biomedical talent pool of over 58,000 R&D personnel.[3] Early traction came swiftly through internal R&D capabilities, building a pipeline of clinical-stage assets; by 2025, programs like QA108 (Phase 3 for age-related macular degeneration) and YY003 (Phase 2 for glabellar frown lines) demonstrate pivotal progress, including ongoing trials starting as recently as July 2025.[5]
MingMed stands out in biotech through these key strengths:
MingMed rides China's biomedical boom, particularly Guangdong's drive to create a 1 trillion yuan industry cluster amid the Greater Bay Area's (GBA) emphasis on biotech innovation.[3] Its timing aligns with national priorities for original, first-in-class drugs over generics, fueled by talent influx, foreign investment ease in hubs like Hong Kong, and policy support for basic research.[3] Market forces like rising demand for ophthalmology, oncology, and aesthetic treatments favor its pipeline, while it influences the ecosystem by validating GBA as a drug discovery hotspot—exemplified by executive insights on Hong Kong's role in funding high-return innovations.[3] This positions MingMed as a bridge between China's manufacturing scale and global unmet needs.
MingMed is poised for commercialization milestones, with Phase 3 assets like QA108 potentially launching soon and new trials (e.g., Phase 1/2 oncology in 2025) expanding its reach.[5] Trends like AI-aided discovery, GBA integration, and global demand for novel biologics will accelerate its trajectory, potentially evolving it into a multi-billion player via partnerships or IPOs. As a 2019-founded trailblazer raising $110M early, MingMed exemplifies how targeted R&D in synergistic areas can redefine China's pharma presence, delivering drugs that truly address unmet needs.[1][3]
MingMed has raised $110.0M across 2 funding rounds. Most recently, it raised $50.0M Series A in September 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2021 | $50.0M Series A | Gaorong Capital, Lightspeed China Partners | |
| Mar 1, 2021 | $60.0M Series A | Gaorong Capital, Lightspeed China Partners |